Ligand validation:3FO3

PG6: 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3FO3_PG6_A_532	58%	79%	0.112	0.9	0.51	0.35	-	-	3	0	94%	0.5
3FO3_PG6_B_532	43%	74%	0.145	0.879	0.56	0.45	-	-	2	0	94%	0.5
3FO3_PG6_B_542	31%	87%	0.093	0.89	0.42	0.27	-	-	0	0	28%	0.5
3FO3_PG6_B_535	28%	74%	0.134	0.883	0.44	0.58	-	-	1	0	44%	1
3FO3_PG6_A_534	21%	84%	0.129	0.838	0.53	0.24	-	-	0	0	44%	1
3FO3_PG6_A_536	12%	88%	0.122	0.741	0.5	0.19	-	-	3	0	50%	0.5
3FO3_PG6_A_543	6%	76%	0.183	0.702	0.51	0.43	-	-	2	0	56%	0.5
3FO3_PG6_A_542	6%	83%	0.284	0.84	0.38	0.4	-	-	5	0	28%	0.5
3SCE_PG6_A_524	59%	77%	0.071	0.961	0.46	0.46	-	-	1	0	39%	1
3LG1_PG6_A_532	42%	49%	0.143	0.872	0.83	1.13	-	2	0	0	94%	0.941
3MMO_PG6_B_529	24%	80%	0.107	0.862	0.53	0.32	-	-	0	0	28%	1
3OWM_PG6_A_526	23%	70%	0.14	0.813	0.6	0.55	-	-	0	0	72%	1
3D1I_PG6_A_1010	23%	76%	0.17	0.831	0.5	0.46	-	-	9	0	78%	0.5
7FCN_PG6_A_201	82%	84%	0.085	0.938	0.53	0.25	-	-	2	0	100%	0.53
3ON2_PG6_C_201	78%	72%	0.085	0.927	0.5	0.59	-	-	0	0	100%	1
6ZL7_PG6_A_402	77%	81%	0.072	0.96	0.24	0.58	-	-	0	0	72%	1
5FIP_PG6_B_1393	71%	75%	0.094	0.914	0.57	0.4	-	-	3	0	100%	1
6QLA_PG6_A_403	71%	87%	0.089	0.949	0.31	0.37	-	-	0	0	78%	0.5

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.